This publication has been discontinued on August 16, 2012.
Abstract
Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: IRELAND - REVIEW
Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country is in the midst of a severe economic downturn, with GDP expected to contract in 2012. Due to the recession and Ireland's huge budget deficit, the country has received an 85 billion euro (US$113 billion) bailout from the EU and IMF. As a result, the government faces an extremely tight financial operating environment in the next few years. It has generally sought to protect healthcare, especially frontline services, from the kinds of cuts experienced elsewhere, but health is not unaffected. A progression of measures has been introduced as the economic position has worsened, most recently the Budget 2011 and related National Recovery Plan.
In March 2011, the government announced plans to introduce Universal Health Insurance (UHI) by 2016. Underpinning the UHI system will be the principle of access according to need and payment according to ability to pay. Insurance with a public or private insurer will be compulsory, with insurance payments related to ability to pay. The government is also planning to remove fees for GP care, which will be implemented in phases, firstly for claimants of free drugs under the Long-Term Illness scheme and the High-Tech Drugs scheme, before being extended to all. Under UHI, public hospitals will no longer be managed by the HSE. They will be independent, not-for-profit trusts with managers accountable to their boards. Hospitals will be paid according to the care they deliver and will be incentivised to deliver more care in a 'money follows the patient' system. The government has also reiterated plans to introduce reference pricing and generic substitution, as cost saving measures.
Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer's Lipitor and Eli Lilly's Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
More Information...
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
Table of Contents
EXECUTIVE SUMMARY
- Snapshot: Strategic Espicom Analysis
- Snapshot: Key Data Projections
MACROENVIRONMENT
- POLITICAL
- ECONOMIC
- Projections
- Ireland Receives 85.0 billion euro (US$112.7 billion) Bailout from the
EU and IMF
- LEGAL
- EU Patent Protection & Intellectual Property Rights
- Proposal for Unitary Patent
- EU Supplementary Protection Certificates
- EU Data Exclusivity
- DEMOGRAPHIC
- Projections
- Demographic Indicators
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
EPIDEMIOLOGY
- DISEASE BURDEN
- Leading Causes of Mortality
- DISEASE PREVALENCE
- Communicable Diseases
- Non-Communicable Diseases
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
- EU DIRECTIVE
- Cross-Border Healthcare Directive
- ORGANISATION
- National Healthcare Bodies
- Structure
- EXPENDITURE
- Projections
- Latest Figures
- National Recovery Plan
- Universal Social Charge
- Cost-Containment Measures
- Private Health Expenditure
- INFRASTRUCTURE
- Hospital Infrastructure
- Infrastructure Investments - HSE Capital Plan 2010
- Private Hospital Operators
- Barringtons Hospital
- Bon Secours Health System
- Galway Clinic
- Mater Private Hospital
- Mount Carmel Medical Group
- St Francis Private Hospital
- St Vincent's Private Hospital
- SERVICES
- Hospital Inpatient Services
- Outpatient Services
- WORKFORCE
- Projections
- Public Health Workforce
- Hospital Physicians
REGULATORY AFFAIRS
- EU REGULATORY AUTHORITY
- NATIONAL AUTHORITIES
- MARKETING REGISTRATION
- EU Marketing Registration
- National Procedures
- PROMOTION
PRICING & REIMBURSEMENT
- EU NETWORKING MEETING
- NM CAPR
- PRICING
- Reference Pricing and Generic Substitution
- Price Cuts for Patent-Expired Brands
- Prescription Charges
- Wholesale Price Margins
- Pharmacy Mark-ups
- REIMBURSEMENT
DISTRIBUTION CHANNELS
- EU DIRECTIVE
- Falsified Medicines Directive
- DRUG WHOLESALING
- Leading Wholesalers
- Cahill May Roberts (Celesio)
- Uniphar Group
- United Drug Wholesale
- DRUG RETAILING
- Leading Pharmacy Chains
- Alliance Boots
- Unicare Pharmacies (Celesio)
MARKET ANALYSIS
- SIZE
- Projections
- Historical Figures
- Current Structure
PRODUCT DEVELOPMENT
- EU Programmes
- National Research & Development
- Global Pharmaceutical Centre of Excellence
- MANUFACTURING
- TRADE
- Exports
- Imports
- Balance of Trade
COMPETITION
- TRADE ASSOCIATIONS
- Irish Pharmaceutical Healthcare Association
- COMPANY INTELLIGENCE
- Abbott Laboratories
- Alkermes
- Allergan
- Astellas
- Bristol-Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Helsinn
- Hovione
- Johnson & Johnson
- Leo Pharma
- MSD
- Novartis
- Pfizer
- Recordati
- Roche
- Servier
- Shire Pharmaceuticals
- Takeda
- Warner Chilcott
- Competitive Strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
- REGULATION
- EU Marketing Registration
- PRICING & REIMBURSEMENT
- MARKET SIZE
- COMPETITION
- Trade Association
- Association of Pharmaceutical Manufacturers of Ireland (APMI)
- Company Intelligence
- Actavis
- Athlone Laboratories
- Gerard Laboratories (Mylan)
- Niche Generics
- Pinewood Healthcare
- Stada Arzneimittel
- Teva Pharmaceuticals Ireland
BIOLOGICS & BIOSIMILARS
- REGULATION
- EU Approval Process
- EU Regulation of Biosimilars
- EMA Guideline Documents
- Draft Biosimilar Concept Paper
- Biosimilar mAb Guideline
- Biosimilars Approved in the EU
- COMPETITION
- Company Intelligence
- Amarin
- Centocor Ortho Biotech
- Eli Lilly
- FMC BioPolymer
- MSD
- Pfizer
- PPD
CONCLUSIONS: OPPORTUNITIES & CHALLENGES
- Strategic Espicom Analysis
- MACROENVIRONMENT
- EPIDEMIOLOGY
- HEALTHCARE
- REGULATORY AFFAIRS
- PRICING & REIMBURSEMENT
- DISTRIBUTION CHANNELS
- MARKET
- COMPETITION
- OTC PHARMACEUTICALS
- GENERIC PHARMACEUTICALS
- BIOLOGICS & BIOSIMILARS
- Radar Analysis
- SWOT Analysis
DIRECTORY
- GOVERNMENT ORGANISATIONS
- PHARMACEUTICAL COMPANIES
- Generic Companies
- Biotechnology Companies
- PHARMACEUTICAL DISTRIBUTORS
- PHARMACY CHAINS
- TRADE ORGANISATIONS
List of Tables
- Espicom Analysis of the Pharmaceutical Market, 2012
- Key Data Projections, 2012-2017
- Political Landscape, 2012
- Regional Ranking of Projected Economies, 2017
- Projected Economy, 2012-2017
- Regional Ranking of Projected Demographics, 2017
- Projected Demographics, 2012-2017
- Projected Population by Age Group, 2025 & 2050 (000s)
- Principal Causes of Death, 2005-2009
- Reported Infectious Diseases, 2007-2009
- Regional Ranking of Projected Health Expenditure, 2017
- Projected Health Expenditure, 2012-2017
- Estimated Gross Healthcare Expenditure, 2010-2011 (Euro Million)
- HSE Expenditure by Type, 2010-2011 (Euro 000s)
- Public Health Expenditure Ceilings, 2011-2014 (Euro Million)
- Acute Public Hospital Activity, 2004-2009
- Outpatient Visits to Acute Public Hospitals, 2004-2008
- Regional Ranking of Projected Physicians, 2017
- Projected Physicians, 2012-2017
- Public Health Service Employment by Category, 2006-2010
- Consultant & Non-Consultant Hospital Physicians, 2006-2010
- Irish Medicines Board Activity, 2004-2009
- Number of Community Pharmacies, 2007-2011
- Regional Ranking of Projected Pharmaceutical Markets, 2017
- Projected Pharmaceutical Market at Retail Prices, 2012-2017
- Historical Pharmaceutical Market at Retail Prices, 1995-2011
- Payments to Pharmacists Under Community Drug Schemes, 2004-2008 (Euro
Millions)
- GMS Expenditure by Leading Therapy Areas, 2008-2009 (Euro Millions)
- Pharmaceutical Production, 1995-2010 (Euros 000s)
- Pharmaceutical Exports by Category, 1995-2010 (US$000s)
- Pharmaceutical Exports by Country/Region, 2010 (US$000s)
- Pharmaceutical Imports by Category, 1995-2010 (US$000s)
- Imports of Raw Materials by Country/Region, 2010 (US$000s)
- Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s)
- Imports of Medicaments by Country/Region, 2010 (US$000s)
- Balance of Pharmaceutical Trade, 1995-2010 (US$000s)
- Members of the IPHA, 2011
- OTC Sales at Retail Prices by Product Group, 2008-2010 (Euro Millions)
- Biosimilars Approved in the EU
- Espicom Analysis of the Pharmaceutical Market, 2012
- SWOT Analysis of the Pharmaceutical Market, 2012
List of Charts
- Regional Comparison of Top 6-16 Projected Pharmaceutical Markets at Retail
Prices, 2017
- Historical Pharmaceutical Market at Retail Prices, 1995-2011
- Pharmaceutical Exports, 1995-2010 (US$ Billions)
- Pharmaceutical Exports by Country/Region, 2010 (%)
- Pharmaceutical Imports, 1995-2010 (US$ Billions)
- Imports of Pharmaceuticals by Country/Region, 2010 (%)
- Balance of Pharmaceutical Trade, 1995-2010 (US$ Billions)
- Radar Graph of the Pharmaceutical Market, 2012
